WO2004058222A1 - High pressure compaction for pharmaceutical formulations - Google Patents
High pressure compaction for pharmaceutical formulations Download PDFInfo
- Publication number
- WO2004058222A1 WO2004058222A1 PCT/US2003/041392 US0341392W WO2004058222A1 WO 2004058222 A1 WO2004058222 A1 WO 2004058222A1 US 0341392 W US0341392 W US 0341392W WO 2004058222 A1 WO2004058222 A1 WO 2004058222A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pressure
- gpa
- fused
- particles
- active pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
Definitions
- the invention relates to the field of pharmacology and, in particular, to sustained-release formulations for active pharmaceutical ingredients.
- the invention also relates to methods for preparing such formulations by high pressure compaction of an active pharmaceutical ingredient.
- microparticles have been used to prepare solutions or suspensions for oral, subcutaneous, intravenous, intramuscular or other injectable routes of administration; have been mixed with binding agents and pressed into pills or tablets for oral or rectal administration; and have been mixed with matrix materials to create implants in which the active pharmaceutical ingredient dissolves from the implant over time.
- an active pharmaceutical ingredient is administered in a sustained-release formulation, typically with the objective of achieving nearly constant or zero-order kinetics of release over a sustained period of time.
- sustained-release systems in the prior art have employed a finely milled or micronized preparation of the active pharmaceutical ingredient as a starting point in the formulations.
- the release of the active pharmaceutical ingredient into the body is then controlled using matrices, membranes or other inactive ingredients or devices.
- examples of methods and devices known in the art for sustained release formulations include liposomes, bioerodible matrices (e.g., PLA/PGLA matrices), drug-permeable implants (e.g., U.S. Pat. No. 3,993,073 to Zaffaroni), implants with drug-permeable and drug-impermeable membranes (e.g., U.S. Pat. No. 5,378,475 to Smith et al.), and osmotic drug delivery systems (e.g., U.S. Pat. No.4,439,196 to Higuchi).
- compositions particles can be produced by constructive or destructive means.
- Constructive means include crystallization, spray drying, freeze drying, and supercritical fluid techniques.
- Destructive techniques include machining or milling using compressive forces, shear and tension forces. See, e.g., Crowder et al., A Guide to Pharmaceutical Particulate Science, (2003), CRC Press, pgs. 9-26.
- sustained-release formulations active pharmaceutical ingredients are usually machined or milled to produce small or micronized crystals of the drug, which are then combined with matrices, semi-permeable membranes, pumps or other inactive ingredients or devices in order to achieve the effect of sustained-release delivery.
- Prior art sustained-release delivery systems with large particles of an active pharmaceutical ingredient such as insulin, corticosteroids, or penicillins, employ techniques as solvation crystallization, thermal crystallization, or seeding crystallization to produce the larger particles.
- the present invention depends, in part, upon the discovery that the application of high pressure compaction to powdered or micronized pharmaceutical preparations can cause physical but non-chemical transformations to an alternative state with substantially slower rates of dissolution and, consequently, increased utility in the preparation of sustained-release formulations.
- pharmaceutical preparations subjected to high pressure compaction exhibit dissolution kinetics which are superior to conventional crystalline or amorphous packed powder preparations for sustained-release administration of active pharmaceutical ingredients.
- the present invention provides methods for producing a pharmaceutical preparation of pressure-fused particles including an active pharmaceutical ingredient by providing a sample including the active pharmaceutical ingredient in crystalline or amorphous form; subjecting the sample to high pressure compaction at a pressure of between 0.1 GPa and 10 GPa to produce a compacted sample; and isolating pressure-fused particles from the compacted sample.
- the pressure is between 0.5 GPa and 7.5 GPa. In other embodiments, the pressure is between 1 GPa and 5 GPa.
- the amount of pressure is sufficient to produce a compacted sample having a density of between 1 g/cm 3 and 40 g/cm 3 , between 2 g/cm 3 and 20 g/cm 3 , and between 4 g/cm 3 and 10 g/cm 3 . In some embodiments, the amount of pressure is sufficient to produce pressure-fused microparticles having a density of between 1 g/cm 3 and 40 g/cm 3 , between 2 g/cm 3 and 20 g/cm 3 , and between 4 g/cm and 10 g/cm . In some embodiments, the compacted sample has a thickness of between 25 ⁇ m and 400 ⁇ m. In other embodiments, the compacted sample has a thickness of between 50 ⁇ m and 200 ⁇ m. In yet other embodiments, the compacted sample has a thickness of between 100 ⁇ m and 150 ⁇ m.
- the pressure is maintained for a period of between 30 sec. and 10 min. In other embodiments, the pressure is maintained for a period of between 60 sec. and 5 min. In yet other embodiments, the pressure is maintained for a period of between 90 sec. and 3 min.
- the pressure-fused particles have a maximum dimension between 20 ⁇ m and 800 ⁇ m. In other embodiments, the pressure-fused particles have a maximum dimension between 40 ⁇ m and 400 ⁇ m. In yet other embodiments, the pressure-fused particles have a maximum dimension between 100 ⁇ m and 250 ⁇ m.
- the step of isolating the pressure-fused particles from the compacted sample comprises sieving the compacted sample through a sieve with an exclusion limit of between 20 ⁇ m and 800 ⁇ m. In other embodiments, the exclusion limit is between 40 ⁇ m and 400 ⁇ m. In yet other embodiments, the exclusion limit is between 100 ⁇ m and 250 ⁇ m.
- the sample prior to compaction includes micronized particles including the active pharmaceutical ingredient.
- the invention provides pharmaceutical preparations of pressure-fused particles comprising an active pharmaceutical ingredient in which the pressure-fused particles include an active pharmaceutical ingredient subjected to high pressure compaction at a pressure of between 0.1 GPa and 10 GPa. In some embodiments, the pressure is between 0.5 GPa and 7.5 GPa. In other embodiments, the pressure is between 1 GPa and 5 GPa.
- the pressure-fused particles have a maximum dimension between 20 ⁇ m and 800 ⁇ m. In other embodiments, the pressure-fused particles have a maximum dimension between 40 ⁇ m and 400 ⁇ m. In yet other embodiments, the pressure-fused particles have a maximum dimension between 100 ⁇ m and 250 ⁇ m.
- Figure 1 presents data regarding the in vitro release of the active pharmaceutical ingredient olanzapine from coated microparticles of the invention over a sustained-release period.
- Figure 2 presents data regarding the in vivo release of the active pharmaceutical nifedipine from a compacted sample including pressure-fused microparticles of the invention over a sustained-release period.
- Figure 3 presents data regarding the in vivo release of the active pharmaceutical carbamazepine from a compacted sample including pressure-fused microparticles of the invention over a sustained-release period.
- Figure 4 presents data regarding the in vivo release of the active pharmaceutical cyclosporine from a compacted sample including pressure-fused microparticles of the invention over a sustained-release period.
- Figure 5 presents data regarding the in vivo release of the active pharmaceutical ciprofloxacin from a compacted sample including pressure-fused microparticles of the invention over a sustained-release period.
- the particles of the invention are substantially spherical in some embodiments, the particles can be any solid geometric shape which is not inconsistent with the principles of the invention, including, without limitation, ellipsoids, cylinders, polyhedrons, disks and irregular shapes.
- Disk means any solid body which is significantly smaller in a first dimension relative to the two perpendicular dimensions. Such bodies may be variously described as disks, wafers, or planar bodies, including, without limitation, bodies which are circular, elliptical or polygonal in the plane perpendicular to the first dimension.
- active pharmaceutical ingredient means any compound which has utility as a pharmaceutical or drug, including, without limitation, naturally occurring compounds (e.g., hormones) and synthetic drugs.
- Sustained Release means continued release of a compound from a reservoir or source over a period of time.
- Parenteral Administration means introduction of a pharmaceutical preparation into the body by a route other than the alimentary canal or digestive tract, including, without limitation, subcutaneous , intravenous, intramuscular and intraocular injection as well as surgical implantation.
- Polymeric Coating means any coating which is formed by polymerization of one or more monomers to form linear or branched or cross-linked macromolecules.
- the coating may be variously characterized as a coating, layer, membrane, shell, capsule, or the like, and must substantially surround or envelope the core particles of the invention.
- Permeable As used herein, the term " permeable" means allowing passage of molecules by diffusion but not by fluid flow.
- Semi-Permeable As used herein, the term “semi-permeable” means permeable to some molecules but not to others. As used herein, semi-permeable polymeric coatings are permeable to at least water and the active pharmaceutical ingredient within the particles of the invention.
- Biocompatible means characterized by not causing a toxic, injurious or immunological response when brought into contact with living tissue, particularly human or other mammalian tissue.
- Biodegradable means capable of partially or completely dissolving or decomposing in living tissue, particularly human or other mammalian tissue. Biodegradable compounds can be degraded by any mechanism, including, without limitation, hydrolysis, catalysis and enzymatic action.
- Pseudo-Zero-Order Kinetics As used herein, the term "pseudo-zero-order kinetics" means sustained-release of the active pharmaceutical ingredient which exhibits kinetics which is zero-order (i.e., independent of concentration) or between zero-order and first order (i.e., proportional to concentration) kinetics over the sustained-release period, where the concentration is based on the total amount of the active pharmaceutical ingredient contained within the particles. In some embodiments, the release exhibits kinetics which are less than proportional to the square root of the concentration of the active pharmaceutical ingredient over the sustained-release period.
- a variable which is described as having values between 0 and 2 can take the values 0, 1 or 2 if the variable is inherently discrete, and can take the values 0.0, 0.1, 0.01, 0.001, or any other real values > 0 and ⁇ 2 if the variable is inherently continuous.
- the present invention depends, in part, upon the discovery that the application of high pressure compaction to powdered or micronized pharmaceutical preparations can cause physical but non-chemical transformations to an alternative state with substantially slower rates of dissolution and, consequently, increased utility in the preparation of sustained-release formulations.
- pharmaceutical preparations subjected to high pressure compaction exhibit dissolution kinetics which are superior to conventional crystalline or amorphous packed powder preparations for sustained-release administration of active pharmaceutical ingredients.
- high pressure compaction causes a physical but non-chemical transformation of state to form pressure-fused particles which, in some embodiments, exhibit hyaline or glassy characteristics but, in other embodiments, retain crystalline or amorphous characteristics.
- the resultant pressure-fused particles have different dissolution characteristics and, in particular, slower rates of dissolution.
- the high pressure compaction exceeds the apparent glass transition pressure of the pharmaceutical preparation and/or active pharmaceutical ingredient.
- the resultant pressure-fused particles exhibit a hyaline or glassy appearance.
- the sample is rotated during the application of an initial pressure to distribute the material evenly within the press.
- the amount of sample applied to the press is chosen such that the thickness of the material after high pressure compaction is between 25 ⁇ m and 400 ⁇ m, between 50 ⁇ m and 200 ⁇ m, or between 100 ⁇ m and 150 ⁇ m.
- the amount of pressure required to produce the pressure-fused particles of the invention is between 1 mton/cm 2 and 100 mton/cm 2 , between 5 mton/cm 2 and 75 mton/cm 2 , or between 10 mton/cm 2 and 50 mton/cm 2 .
- the pressure can be between approximately 0.1 GPa and 10 GPa, between 0.5 GPa and 7.5 GPa, or between 1 GPa and 5 GPa. In some embodiments, this pressure is applied for a period of between 30 sec. and 10 min., between 60 sec.
- the amount of pressure is sufficient to produce a compacted sample having a density of between 1 g/cm 3 and 40 g/cm 3 , between 2 g/cm 3 and 20 g/cm 3 , and between 4 g/cm 3 and 10 g/cm 3 . In some embodiments, the amount of pressure is sufficient to produce pressure-fused microparticles having a density of between 1 g/cm 3 and 40 g/cm 3 , between 2 g/cm 3 and 20 g/cm 3 , and between 4 g/cm 3 and 10 g/cm 3 .
- the invention also depends, in part, upon the recognition that, if a larger particle of a pharmaceutical preparation is introduced, there will be a sustained-release effect due to the decreased surface area-to-volume ratio of the larger particles.
- the particle if the particle is formulated to be substantially flat or planar, then the kinetics of drug release will more nearly approximate constant or zero-order kinetics.
- the particles of the invention can be used for parenteral administration.
- the administration will be by injection (e.g., subcutaneous, intravenous, intramuscular, intraocular), or by introduction to a wound site or during surgery (e.g., lavage or irrigation of a wound or surgical site).
- the particles can be sufficiently small to form a suspension and, in certain embodiments, the particles can be sufficiently small for injection through a hypodermic needle.
- the particles have a maximum dimension of between 20 ⁇ m and 800 ⁇ m, between 40 ⁇ m and 400 ⁇ m, or between 100 ⁇ m and 250 ⁇ m.
- the resulting compacted sample can be subjected to sieving to obtain particles of a desired size.
- the compacted sample can be pressed through a sieve with an exclusion limit of between 20 ⁇ m and 800 ⁇ m, between 40 ⁇ m and 400 ⁇ m, or between 100 ⁇ m and 250 ⁇ m.
- the compacted samples or sieved particles can be subjected to milling to produce fused particles of smaller size or with different geometries. For example, in some embodiments, pressure-fused particles are milled to produce spheres whereas in other embodiments the pressure-fused particles are milled to produce disks.
- the pressure-fused particles produced have at least one linear dimension greater than 20 ⁇ m, greater than 40 ⁇ m, greater than 100 ⁇ m, greater than 250 ⁇ m, greater than 400 ⁇ m, or greater than 800 ⁇ m.
- at least 70%, 80%, 90% or 95% of the particles have at least one linear dimension greater than 20 ⁇ m, greater than 40 ⁇ m, greater than 100 ⁇ m, greater than 250 ⁇ m, greater than 400 ⁇ m, or greater than 800 ⁇ m.
- the pressure-fused particles of the invention can optionally be encapsulated or coated with a polymeric layer or coating according to any method known in the art or subsequently developed.
- a polymeric layer or coating can be useful for improving the sustained-release properties of the particles, or for improving characteristics including, without limitation, administrability, palatability, stability, or shelf-life.
- biocompatible and biodegradable polymers examples include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly( ⁇ -caprolactone) (PCL), poly(valerolactone) (PVL), poly( ⁇ -decalactone) (PDL), poly(l,4-dioxane-2,3-dione), poly(l,3-dioxane-2-one), poly(para-dioxanone) (PDS), poly(hydroxybutyric acid) (PHB), poly(hydroxyvaleric acid) (PHV), and poly( ⁇ -malic acid) (PMLA).
- PLA poly(lactic acid)
- PGA poly(glycolic acid)
- PLA poly(lactic-co-glycolic acid)
- PCL poly( ⁇ -caprolactone)
- PVL poly(valerolactone)
- PVL poly( ⁇ -decalactone)
- PDS poly(
- useful polymers include, without limitation, naturally occurring polymers including carbohydrates such as sugar phosphates, alkylcelluloses (e.g., ethylcellulose), and hydroxyalkylcelluloses (e.g., hydroxypropylcellulose); and synthetic polymers or co-polymers including one or more of the following monomers: lactic acid, glycolic acid, ⁇ -propiolactone, ⁇ -butyrolactone, ⁇ -butyrolactone, pivalolactone, ⁇ -hydroxy butyric acid, ⁇ -hydroxyethyl butyric acid, ⁇ -hydroxy isovaleric acid, ⁇ -hydroxy- ⁇ -methyl valeric acid, ⁇ -hydroxy caproic acid, ⁇ -hydroxy isocaproic acid, ⁇ -hydroxy heptanic acid, ⁇ -hydroxy octanic acid, ⁇ -hydroxy decanoic acid, ⁇ -hydroxy myristic acid, ⁇ -hydroxy stearic acid, ⁇ -hydroxy lignoceric acid, ⁇ -
- Lactic acid co-polymers offer a degree of flexibility in choosing the life of a polymer matrix, because the half-life can be controlled by varying the amount and type of co-monomer used.
- Methods of forming polymeric coatings on particles are well known in the art. For example, standard techniques include solvent evaporation/extraction techniques, in-water drying techniques (see, e.g., U.S. Pat. No. 4,994,281), organic phase separation techniques (see, e.g., U.S. Pat. No. 4,675,19, U.S. Pat. No. 5,639,480), spray-drying techniques (see, e.g., U.S. Pat. No. 5,651,990), triple emulsion techniques (see, e.g., U.S. Pat. No. 4,652,441, U.S. Pat. No. 5,639,480), air suspension techniques, and dip coating techniques.
- the coated microparticles of the invention are administered parenterally.
- the administration is by injection of a suspension of the coated microparticles in a pharmaceutically acceptable carrier, whereas in other embodiments the coated microparticles are administered to an open wound or surgical site.
- Administration by injection includes, without limitation, subcutaneous, intravenous, intramuscular and intraocular injection.
- the coated microparticles must have a maximum dimension which is less than the inner diameter of the needle used for injection.
- larger needles may be employed to accommodate larger coated microparticles, such larger coated microparticles can have decreased ability to form a suspension. Therefore, in some embodiments, the coated microparticles have a maximum dimension less than the inner diameter of standard needles for parenteral injection.
- the coated microparticles can be chosen to have a maximum size which permits formulation as a suspension in a pharmaceutically acceptable carrier.
- the coated microparticles can be administered in a suspension, as described above, or as a solid (e.g., a powder), paste, cream, or ointment.
- the coated microparticles can be administered during lavage or irrigation of a wound or surgical site, and the coated microparticles can be substantially larger.
- Active Pharmaceutical Ingredients are examples of active Pharmaceutical Ingredients.
- Active pharmaceutical ingredients which may be formulated according to the invention include any pharmaceutical which may be subjected to the high pressure compaction methods according to the invention without undergoing chemical alteration or degradation which adversely affects its pharmaceutical utility.
- One of ordinary skill can easily ascertain whether any given active pharmaceutical ingredient is useful in the present invention by preparing a pressure-fused particle and comparing its chemical structure to the active form.
- potentially useful active pharmaceutical ingredients can be selected from groups including corticosteroids, anti-psychotics, anti-depressants, anti-epileptics, anti-Parkinson agents, anesthetics, narcotics, antibiotics, HIV protease inhibitors, reverse transcriptase inhibitors, HMG CoA reductase inhibitors, calcium channel blockers, ⁇ -blockers, angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, taxanes, alkylating agents, immunosuppressive agents, hormones and hormone receptor modulators, as well as other active pharmaceutical ingredients for which sustained-release formulations would be advantageous.
- groups including corticosteroids, anti-psychotics, anti-depressants, anti-epileptics, anti-Parkinson agents, anesthetics, narcotics, antibiotics, HIV protease inhibitors, reverse transcriptase inhibitors, HMG CoA reductase inhibitors, calcium channel blockers, ⁇ -blockers
- corticosteroids include dexamethasone, triamcinolone, fluocinolone, fluocinolone acetonide, cortisone, prednisolone, fluometholone, clobetasone butyrate, triamcinolone acetonide, betamethasone valerate, diflucortolone valerate, fluticasone valerate, hydrocortisone 17-butyrate, mometasone furoate, methylprednisolone acetonate, clobetasol propionate, betamethasone dipropionate, desonide and fluticasone.
- Non-limiting examples of anti-psychotics include benzodiazepines such as olanzapine (ZyprexaTM), clozapine, loxapine, and quetiapine; benzisoxazole derivatives such as risperidone (RisperdalTM) and molindone, and pimozide.
- benzodiazepines such as olanzapine (ZyprexaTM), clozapine, loxapine, and quetiapine
- benzisoxazole derivatives such as risperidone (RisperdalTM) and molindone, and pimozide.
- Non-limiting examples of antidepressants include tertiary amine tricyclics such as amitriptaline, doxepin and imipramine; secondary amine tricyclics such as desipramine and nortrypitylene; tetracyclics such as mirtazapine; triazolopyridines such as trazadole; aminoketones such as buproprion; phenethylamines such as venlafaxine; phenylpiperazines such as nefazadone; and selective serotonin reuptake inhibitors (SSRIs) such as citalopram, fluoxetine, fluvoxamine, paroxetine, and sertaline.
- SSRIs selective serotonin reuptake inhibitors
- Non-limiting examples of anti-epileptics include hydantoins such as dilantin; barbiturates such as phenobarbital; deoxybarbiturates such as primidone; iminostilbenes such as cabamazepine; succinimides such as ethosuximide; benzodiazepines such as clonazepam; as well as valproic acid, gabapentin, levetiracetam, tiagabine, topiramate and zonisamide.
- hydantoins such as dilantin
- barbiturates such as phenobarbital
- deoxybarbiturates such as primidone
- iminostilbenes such as cabamazepine
- succinimides such as ethosuximide
- benzodiazepines such as clonazepam
- valproic acid gabapentin, levetiracetam, tiagabine, topiramate and zonisamide.
- Non-limiting examples of anti-Parkinson agents include levodopa preparations such as levodopa benserazide and levodopa/carbidopa; ergot dopamine agonists such as bromocriptine, cabergoline, and pergolide; non-ergot dopamine agonists such pramipexole, ropinerole, and spomorphine; catechol-O-methyltransferase inhibitors such as entacapone and tolcapone; monoamine oxidase B inhibitors such as selegiline;
- NMDA antagonists such as amantadine; and anticholinergics such as benzhexol, benztropine, biperiden, orphenedrine, and procyclidine.
- anesthetics include procaine (NovocainTM), bupivacaine (MarcaineTM), lidocaine (XylocaineTM), etidocaine, ropivacaine, choloroprocaine, tetracaine and mepivacine.
- Non-limiting examples of narcotics include morphine, hydromorphone, meperidine, fentanyl, propoxyphene, levorphanol, codeine, hydrocodone, oxymorphone, levomethadyl acetate, oxycodone and methadone.
- antibiotics include tetracycline antibiotics, such as tetracycline, chlortetracycline, oxytetracycline, demeclocycline, methacycline, doxycycline, and minocycline; penicillin antibiotics such as penicillin, chlorpenicillin, oxypenicillin, methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, bacampicillin, carbenicillin, carbenicillin indanyl, ticarcillin, mezlocillin and piperacillin; macrolide antibiotics such as erythromycin, clarithromycin and azithromycin; fluoroquinolone antibiotics such as norfloxacin, ciprofloxacin, ofoxacin, sparfloxacin, lomefloxacin, fleroxacin, perfloxacin, levofloxacin, trovafloxacin, gatifloxacin, mo
- HIV protease inhibitors include ritonavir, indinavir, nelfinavir, saquinavir, amprenavir and lopinavir.
- nucleoside reverse transcriptase inhibitors include the nucleoside-based reverse transcriptase inhibitors zidovudine, didanosine, stavudine, zalcitabine, lamuvidine, and abacavir, and the non-nucleoside-based reverse transcriptase inhibitors include delavirdine, efavirenez and nevirapine.
- Non-limiting examples of HMG Co-A reductase inhibitors include simvastatin (ZocorTM), lovastatin (MevacorTM), atorvastatin (LipitorTM), pravastatin sodium, fluvastatin and cerivastatin
- Non-limiting examples of calcium channel blockers include dihydropyridines, such as nifedipine; phenyl alkyl amines, such as verapamil; and benzothiazepines, such as diltiazem; as well as amrinone, amlodipine, bencyclane, felodipine, fendihne, flunarizine, isradipine, nicardipine, nimodipine, perhexilene, gallopamil, tiapamil, phenytoin, barbiturates, dynorphin, omega-conotoxin, and omega-agatoxin.
- Non-limiting examples of ⁇ blockers include propranolol, atenolol, acebutolol, alprenolol, befunolol, betaxolol, bunitrolol, carteolol, celiprolol, hedroxalol, indenolol, labetalol, levobunolol, mepindolol, methypranol, metindol, metoprolol, metrizoranolol, oxprenolol, pindolol, practolol, sotalolnadolol, tiprenolol, tomalolol, timoiol, bupranolol, penbutolol and trimepranol.
- Non-limiting examples of angiotensin II receptor antagonists include saralasin.
- Non-limiting examples of ACE inhibitors captopril, zofenopril, enalapril, lisinopril, quinapril, ramipril, perindopril, cilazapril, benazapril, fosinopril and trandolopril.
- Non-limiting examples of taxanes include paclitaxel and docetaxel.
- Non-limiting examples of alkylating agents include the nitrogen mustards, alkyl sulfonate, nitrosurea, ethylenimine and methylmelamine, triazene classes, cyclophosphamide, ifosamide, thiotepa, melphalan, busulfan, carmustine, clorambucil, hexamethylmelamine and streptozocin.
- Non-limiting examples of immunosuppressive agents that suppress the immune system includes the corticosteroids, the purine antagonists such as azathioprine, cyclosporine, tacrolimun, sirolimus and mycophenolate mofetil.
- hormones and hormone receptor modulators include insulin, pituitary growth hormone, adrenocorticotrophic hormone, testosterone, progesterone, estrogen, levonorgestrel (NorplantTM), tamoxifen, raloxifen and fulvestrant.
- Non-limiting examples of other active pharmaceutical ingredients potentially useful in the invention include vinca alkaloids such as vincristine and vinblastine; platinum coordination complexes such as cisplatin and carboplatin; isoflavones such as genistein, formomonetin, daidzein and equol; epidophylotoxins such as etoposide and teniposide; camptothecins such as topotecan,and crizecan; folic acid analogues such as methotrexate; pyrimidine analogues such as 5-fluorouracil, floxuridine, and cytosine arabinoside; and purine analogues such as 6-mercaptopurine, 6-thioguanine, and 2-deoxycoformycin; as well as the anti-alcoholism medication disulfiram
- Pressure-fused particles were prepared from the active pharmaceutical ingredient olanzapine, an atypical antipsychotic drug, obtained in micronized form (90% of particles ⁇ 5 ⁇ m in diameter) from a commercial supplier (Dr. Reddy Labs, Upper Saddle River, NJ).
- the lower punch of a hydraulic press used for producing IR pellets was placed into a die with an 8 mm diameter, and approximately 30 mg of olanzapine was loaded into the die.
- the upper punch was placed into the die, and moderate pressure was applied by hand to pack and evenly distribute the active pharmaceutical ingredient in the die.
- the die assembly was seated in the press and force was increased to 25-30 mtons and maintained for a minimum of 30 seconds, and typically 90 seconds.
- the area of the die was approximately 0.50 cm and, therefore, the pressure was 50-60 mtons/cm .
- 1 GPa is equal to 10.197 mtons/cm 2
- the pressure was approximately 5-6 GPa.
- the density of the compacted sample was approximately 4 g/cm 3 .
- the high pressure compaction produced a "fused" or “glassy” wafer of olanzapine that was removed from the press.
- the compacted sample was then forced through a 60 mesh sieve grating with apertures of approximately 250 ⁇ m to produce roughly cuboidal particles.
- Poly vinyl alcohol (PVA) was obtained with a mol. wt. range of 124,000- 186,000. Excess PVA was heated in water at 65 °C. After cooling, the PVA solution was decanted and mixed with core particles prepared as described above. The core particles were swirled in a beaker of the PVA solution for several seconds, and vacuum-filtered onto #42 filter paper (Whatman, Inc., Clifton, NJ) in a 9 cm diameter Buchner funnel. The filter paper with retained coated core particles was transferred to a watch glass and dried at 155°C or 165°C for 10 minutes. This process was repeated 4-5 times.
- micronized olanzapine (90% of particles ⁇ 5 ⁇ m in diameter) from a commercial supplier (Dr. Reddy Labs, Upper Saddle River, NJ) was compared with the dissolution of coated microparticles of olanzapine prepared as described above. Powder dissolution testing was carried out in distilled water at 25°C. A 2-3 mg sample of the powder in 25 ml of water was 50% dissolved at approximately 1 minute, and was completely dissolved in 2.5 minutes.
- Coated microparticle dissolution testing was also carried out in distilled water at 25°C. A 2-3 mg sample was placed in 25 ml of water. The microparticles were completely covered by the solution. Every 24 h for 5 days, 5 ml of the supernatant solution was carefully removed and replaced with fresh media, avoiding mixing of the buffer, to simulate physiological "sink” conditions.
- Figure 1 represents the data regarding the release of the active pharmaceutical ingredient from the coated microparticles over time. As shown in the figure, the rate of release was substantially constant or pseudo-zero-order over several days. The release rate from the PVA- coated microparticles dried at the lower temperature was greater, indicating that drying temperature can be used to vary permeability and release rate.
- HPLC high performance liquid chromatography
- the active pharmaceutical ingredients nifedipine (a calcium channel blocker), carbamazepine (an anti-epileptic), cyclosporine (an immunosuppresive agent), and ciprofloxacin (an antibiotic) were prepared as compacted samples according to the methods of the invention.
- a sample of 30-40 mg of the active pharmaceutical ingredient was subjected to very high pressure compaction of approximately 5-6 GPa to produce a compacted sample measuring approximately 8 mm in diameter and approximately 125-200 ⁇ m in thickness.
- the resulting compacted sample was broken into fragments to weigh-out an appropriate amount for administration to animals as described below.
- 3-5 male Sprague-Dawley rats were cannulated through the jugular vein to allow venous access.
- ketamine 60 mg/kg
- medetomidine 0.3 mg/kg
- the backs of the rats were shaved and an incision approximately 6 mm in length was made in the skin.
- the subcutaneous tissues were spread using blunt scissors and 6 mg/kg of the compacted sample was placed into the subcutaneous tissues approximately 5 mm from the incision site. The incision was closed with staples and topical antibiotic applied.
- Venous samples were taken through the cannula periodically for approximately two weeks to determine plasma levels of the active pharmaceutical ingredients.
- the assays had sensitivities of approximately 1 ng/ml. Histological examination of the implantation sites was carried out in all animals. Animals appeared to remain healthy and to gain weight normally. By postmortem histological examination of the implantation sites, there was no evidence of local toxicity, tissue reaction or infection.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002510319A CA2510319A1 (en) | 2002-12-20 | 2003-12-22 | High pressure compaction for pharmaceutical formulations |
AU2003299983A AU2003299983A1 (en) | 2002-12-20 | 2003-12-22 | High pressure compaction for pharmaceutical formulations |
US10/538,991 US20070218139A1 (en) | 2002-12-20 | 2003-12-22 | High Pressure Compaction For Pharmaceutical Formulations |
JP2005510070A JP2006521287A (en) | 2002-12-20 | 2003-12-22 | High pressure compression for pharmaceutical formulations |
EP03800248A EP1583519A1 (en) | 2002-12-20 | 2003-12-22 | High pressure compaction for pharmaceutical formulations |
AU2010201138A AU2010201138A1 (en) | 2002-12-20 | 2010-03-23 | High pressure compaction for pharmaceutical formulations |
Applications Claiming Priority (70)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43537202P | 2002-12-20 | 2002-12-20 | |
US43550802P | 2002-12-20 | 2002-12-20 | |
US43533602P | 2002-12-20 | 2002-12-20 | |
US43550702P | 2002-12-20 | 2002-12-20 | |
US43544502P | 2002-12-20 | 2002-12-20 | |
US43544902P | 2002-12-20 | 2002-12-20 | |
US43563202P | 2002-12-20 | 2002-12-20 | |
US43513202P | 2002-12-20 | 2002-12-20 | |
US43548802P | 2002-12-20 | 2002-12-20 | |
US43549402P | 2002-12-20 | 2002-12-20 | |
US43503702P | 2002-12-20 | 2002-12-20 | |
US43555702P | 2002-12-20 | 2002-12-20 | |
US43516202P | 2002-12-20 | 2002-12-20 | |
US43549502P | 2002-12-20 | 2002-12-20 | |
US43507502P | 2002-12-20 | 2002-12-20 | |
US43556502P | 2002-12-20 | 2002-12-20 | |
US43549602P | 2002-12-20 | 2002-12-20 | |
US43542302P | 2002-12-20 | 2002-12-20 | |
US43563002P | 2002-12-20 | 2002-12-20 | |
US43550502P | 2002-12-20 | 2002-12-20 | |
US43550102P | 2002-12-20 | 2002-12-20 | |
US43541502P | 2002-12-20 | 2002-12-20 | |
US43516302P | 2002-12-20 | 2002-12-20 | |
US43510602P | 2002-12-20 | 2002-12-20 | |
US43503802P | 2002-12-20 | 2002-12-20 | |
US43541602P | 2002-12-20 | 2002-12-20 | |
US43555802P | 2002-12-20 | 2002-12-20 | |
US43544702P | 2002-12-20 | 2002-12-20 | |
US43549702P | 2002-12-20 | 2002-12-20 | |
US43533802P | 2002-12-20 | 2002-12-20 | |
US43538802P | 2002-12-20 | 2002-12-20 | |
US43550602P | 2002-12-20 | 2002-12-20 | |
US43550902P | 2002-12-20 | 2002-12-20 | |
US60/435,496 | 2002-12-20 | ||
US60/435,506 | 2002-12-20 | ||
US60/435,372 | 2002-12-20 | ||
US60/435,037 | 2002-12-20 | ||
US60/435,132 | 2002-12-20 | ||
US60/435,338 | 2002-12-20 | ||
US60/435,416 | 2002-12-20 | ||
US60/435,501 | 2002-12-20 | ||
US60/435,449 | 2002-12-20 | ||
US60/435,415 | 2002-12-20 | ||
US60/435,163 | 2002-12-20 | ||
US60/435,445 | 2002-12-20 | ||
US60/435,507 | 2002-12-20 | ||
US60/435,557 | 2002-12-20 | ||
US60/435,038 | 2002-12-20 | ||
US60/435,388 | 2002-12-20 | ||
US60/435,488 | 2002-12-20 | ||
US60/435,336 | 2002-12-20 | ||
US60/435,075 | 2002-12-20 | ||
US60/435,494 | 2002-12-20 | ||
US60/435,497 | 2002-12-20 | ||
US60/435,565 | 2002-12-20 | ||
US60/435,447 | 2002-12-20 | ||
US60/435,630 | 2002-12-20 | ||
US60/435,509 | 2002-12-20 | ||
US60/435,162 | 2002-12-20 | ||
US60/435,423 | 2002-12-20 | ||
US60/435,495 | 2002-12-20 | ||
US60/435,632 | 2002-12-20 | ||
US60/435,558 | 2002-12-20 | ||
US60/435,505 | 2002-12-20 | ||
US60/435,106 | 2002-12-20 | ||
US60/435,508 | 2002-12-20 | ||
US45072203P | 2003-02-28 | 2003-02-28 | |
US60/450,722 | 2003-02-28 | ||
US45499703P | 2003-03-14 | 2003-03-14 | |
US60/454,997 | 2003-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004058222A1 true WO2004058222A1 (en) | 2004-07-15 |
Family
ID=32686487
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/041391 WO2004058223A1 (en) | 2002-12-20 | 2003-12-22 | Coated particles for sustained-release pharmaceutical administration |
PCT/US2003/041392 WO2004058222A1 (en) | 2002-12-20 | 2003-12-22 | High pressure compaction for pharmaceutical formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/041391 WO2004058223A1 (en) | 2002-12-20 | 2003-12-22 | Coated particles for sustained-release pharmaceutical administration |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1583519A1 (en) |
AU (3) | AU2003299983A1 (en) |
WO (2) | WO2004058223A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007049304A2 (en) * | 2005-10-27 | 2007-05-03 | Jubilant Organosys Limited | Stable coated pharmaceutical formulation of olanzapine and process for preparing the same |
EP1965773A1 (en) | 2005-12-26 | 2008-09-10 | Laboratorios Lesvi, S. L. | Oral formulation of anhydrous olanzapine form i |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US11219604B2 (en) | 2013-03-21 | 2022-01-11 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
US11351124B2 (en) | 2015-10-27 | 2022-06-07 | Eupraxia Pharmaceuticals Inc. | Sustained release of formulations of local anesthetics |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0522474D0 (en) * | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
EP2819741B1 (en) | 2012-02-27 | 2018-03-28 | O-Ray Pharma, Inc. | Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980982A (en) * | 1995-04-13 | 1999-11-09 | Sunitomo Electric Industries, Ltd. | Coated particles for synthesizing diamond and process for production of diamond abrasive for sawing |
US6398991B1 (en) * | 1998-06-25 | 2002-06-04 | Coorstek, Inc. | Processes for making a silicon carbide composition |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2515898A (en) | 1947-09-15 | 1950-07-18 | Lilly Co Eli | Procaine penicillin and therapeutic compositions |
US2627491A (en) | 1950-07-15 | 1953-02-03 | Wyeth Corp | Penicillin salts of substituted alkylene diamines |
US3867519A (en) * | 1972-04-27 | 1975-02-18 | Alza Corp | Bioerodible drug delivery device |
US4623588A (en) | 1984-02-06 | 1986-11-18 | Biotek, Inc. | Controlled release composite core coated microparticles |
US5271946A (en) | 1988-04-20 | 1993-12-21 | Asta Pharma Aktiengesellschaft | Controlled release azelastine-containing pharmaceutical compositions |
-
2003
- 2003-12-22 WO PCT/US2003/041391 patent/WO2004058223A1/en active Application Filing
- 2003-12-22 EP EP03800248A patent/EP1583519A1/en active Pending
- 2003-12-22 WO PCT/US2003/041392 patent/WO2004058222A1/en active Application Filing
- 2003-12-22 AU AU2003299983A patent/AU2003299983A1/en not_active Abandoned
- 2003-12-22 AU AU2003299982A patent/AU2003299982B2/en not_active Expired
-
2010
- 2010-03-23 AU AU2010201138A patent/AU2010201138A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980982A (en) * | 1995-04-13 | 1999-11-09 | Sunitomo Electric Industries, Ltd. | Coated particles for synthesizing diamond and process for production of diamond abrasive for sawing |
US6398991B1 (en) * | 1998-06-25 | 2002-06-04 | Coorstek, Inc. | Processes for making a silicon carbide composition |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007049304A2 (en) * | 2005-10-27 | 2007-05-03 | Jubilant Organosys Limited | Stable coated pharmaceutical formulation of olanzapine and process for preparing the same |
WO2007049304A3 (en) * | 2005-10-27 | 2007-07-26 | Jubilant Organosys Ltd | Stable coated pharmaceutical formulation of olanzapine and process for preparing the same |
EP1965773A1 (en) | 2005-12-26 | 2008-09-10 | Laboratorios Lesvi, S. L. | Oral formulation of anhydrous olanzapine form i |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US8889190B2 (en) | 2013-03-13 | 2014-11-18 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10363224B2 (en) | 2013-03-13 | 2019-07-30 | Upsher-Smith Laboratories, Llc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US9555005B2 (en) | 2013-03-15 | 2017-01-31 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10172878B2 (en) | 2013-03-15 | 2019-01-08 | Upsher-Smith Laboratories, Llc | Extended-release topiramate capsules |
US11219604B2 (en) | 2013-03-21 | 2022-01-11 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
US11351124B2 (en) | 2015-10-27 | 2022-06-07 | Eupraxia Pharmaceuticals Inc. | Sustained release of formulations of local anesthetics |
Also Published As
Publication number | Publication date |
---|---|
AU2003299982A1 (en) | 2004-07-22 |
AU2010201138A1 (en) | 2010-04-15 |
AU2003299983A1 (en) | 2004-07-22 |
WO2004058223A1 (en) | 2004-07-15 |
AU2003299982B2 (en) | 2010-04-29 |
EP1583519A1 (en) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070218139A1 (en) | High Pressure Compaction For Pharmaceutical Formulations | |
AU2010201138A1 (en) | High pressure compaction for pharmaceutical formulations | |
EP0675710B1 (en) | Process for preparing controlled release pharmaceutical forms and the forms thus obtained | |
AU2001287349B2 (en) | Slow release pharmaceutical preparation and method of administering same | |
EP1694305B1 (en) | Pharmaceutical compositions comprising lercanidipine | |
JP2005508301A (en) | Controlled aggregation | |
AU2001287349A1 (en) | Slow release pharmaceutical preparation and method of administering same | |
CN1164389A (en) | Extended release formulation | |
EA021784B1 (en) | Extended-release pharmaceutical formulations | |
CN109328249A (en) | Nanofiber mat containing the ceramic particle with releasable dopant therein | |
CN1794978A (en) | Pharmaceutical compositions comprising atorvastatin manufactured without granulation | |
Rewar et al. | Pulsatile drug delivery system: an overview | |
JP2006528604A (en) | An active substance sustained-release pharmaceutical comprising 6-dimethylaminomethyl-1- (3-methoxy-phenyl) -cyclohexane-1,3-diol | |
JP2015534952A (en) | Long-acting analgesic / PLGA sustained-release agent of dinalbuphine sebacate | |
US20130157992A1 (en) | Sustained drug release and improved product stability using non-covalent particle coating methods | |
JP4754485B2 (en) | Coprecipitation active substance-containing particles | |
CN103768071A (en) | Oral preparation for treating diabetes | |
He et al. | Preparation of lovastatin matrix sustained-release pellets by extrusion-spheronization combined with microcrystal dispersion technique | |
RU2799939C1 (en) | Long-acting dosage form containing rivastigmine and a method of its manufacture | |
WO2004010979A1 (en) | Processes for the preparation of oral dosage formulations of modafinil | |
KR20160124731A (en) | Delayed-release microspheres containing risperidone and a method for manufacturing the same | |
KR20230152051A (en) | FORMULATION OF A MULTILAYERED PELLET COMPRISING MELATONIN | |
KR20160027421A (en) | Delayed-release microspheres containing risperidone and a method for manufacturing the same | |
MXPA06000111A (en) | Process for preparing formulations of lipid-regulating drugs. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005510070 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2510319 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003299983 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003800248 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003800248 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10538991 Country of ref document: US Ref document number: 2007218139 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10538991 Country of ref document: US |